[Skip to Content]
[Skip to Content Landing]
Views 87
Citations 0
Comment & Response
May 4, 2017

Androgen Deprivation Therapy and Subsequent Dementia—Reply

Author Affiliations
  • 1Stanford Center for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, California
  • 2Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia
JAMA Oncol. Published online May 4, 2017. doi:10.1001/jamaoncol.2017.0405

In Reply We thank Welsh and Hentz, and Kim and Chung for their interest in our recent article1 on the association of androgen deprivation therapy (ADT) with increased dementia risk. We agree with Welsh and Hentz that stratification by the form of ADT is an important future step in understanding the association of ADT and the risk of dementia. As the authors highlight, the various forms of ADT used in practice have differing effects on the hypothalamic–pituitary–gonadal axis and could reasonably be hypothesized to have distinct effects on dementia risk. This may explain, and continue to contribute to, variability in effect sizes of studies examining the association of ADT and dementia outcomes. We fully agree with Welsh and Hentz that the analysis of prospective data for men with prostate cancer who received distinct forms of ADT will best clarify the true association of ADT and dementia.

First Page Preview View Large
First page PDF preview
First page PDF preview